AILERON THERAPEUTICS, INC.
490 Arsenal Way, Suite 210
Watertown, MA 02472
October 13, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Aileron Therapeutics, Inc. |
Registration Statement on Form S-1
File No. 333-249319
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aileron Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-249319) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on October 15, 2020, or as soon thereafter as practicable.
| Very truly yours, | ||
| AILERON THERAPEUTICS, INC. | ||
| By: | /s/ Richard J. Wanstall | |
| Name: Richard J. Wanstall | ||
| Title: Chief Financial Officer | ||
| cc: | Stuart M. Falber |
Wilmer Cutler Pickering Hale and Dorr LLP